Free Trial
NASDAQ:AZN

AstraZeneca (AZN) Stock Price, News & Analysis

AstraZeneca logo
$79.99 +0.06 (+0.08%)
Closing price 04:00 PM Eastern
Extended Trading
$79.99 0.00 (0.00%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About AstraZeneca Stock (NASDAQ:AZN)

Key Stats

Today's Range
$79.35
$80.16
50-Day Range
$68.72
$80.97
52-Week Range
$61.24
$87.68
Volume
3.03 million shs
Average Volume
5.24 million shs
Market Capitalization
$248.08 billion
P/E Ratio
30.07
Dividend Yield
1.26%
Price Target
$86.00
Consensus Rating
Moderate Buy

Company Overview

AstraZeneca Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

AZN MarketRank™: 

AstraZeneca scored higher than 52% of companies evaluated by MarketBeat, and ranked 535th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    AstraZeneca has received no research coverage in the past 90 days.

  • Read more about AstraZeneca's stock forecast and price target.
  • Earnings Growth

    Earnings for AstraZeneca are expected to grow by 10.86% in the coming year, from $4.51 to $5.00 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AstraZeneca is 30.09, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.70.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AstraZeneca is 30.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.31.

  • Price to Earnings Growth Ratio

    AstraZeneca has a PEG Ratio of 1.47. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    AstraZeneca has a P/B Ratio of 5.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AstraZeneca's valuation and earnings.
  • Percentage of Shares Shorted

    0.17% of the float of AstraZeneca has been sold short.
  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AstraZeneca has recently decreased by 14.72%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    AstraZeneca pays a meaningful dividend of 1.26%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    AstraZeneca does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of AstraZeneca is 37.97%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 20.20% next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.

  • Read more about AstraZeneca's dividend.
  • Percentage of Shares Shorted

    0.17% of the float of AstraZeneca has been sold short.
  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AstraZeneca has recently decreased by 14.72%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    AstraZeneca has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for AstraZeneca this week, compared to 24 articles on an average week.
  • Search Interest

    Only 36 people have searched for AZN on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AstraZeneca insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 20.35% of the stock of AstraZeneca is held by institutions.

  • Read more about AstraZeneca's insider trading history.
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZN Stock News Headlines

Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
See More Headlines

AZN Stock Analysis - Frequently Asked Questions

AstraZeneca's stock was trading at $65.52 at the start of the year. Since then, AZN stock has increased by 22.1% and is now trading at $80.0060.

AstraZeneca PLC (NASDAQ:AZN) issued its quarterly earnings results on Tuesday, July, 29th. The company reported $1.09 earnings per share for the quarter, hitting analysts' consensus estimates of $1.09. AstraZeneca's quarterly revenue was up 16.1% on a year-over-year basis.
Read the conference call transcript
.

Shares of AstraZeneca split on the morning of Monday, July 27th 2015.The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were distributed to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

AstraZeneca subsidiaries include these companies: Alexion Pharmaceuticals, Takeda Respiratory Business, AcertaPharma, ZS Pharma, Almirall, Pearl Therapeutics, Omthera Pharmaceuticals, and more.

Top institutional shareholders of AstraZeneca include Primecap Management Co. CA (1.33%), Bank of America Corp DE (1.01%), Franklin Resources Inc. (0.69%) and Fisher Asset Management LLC (0.67%).
View institutional ownership trends
.

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include Chevron (CVX), BlackRock (BLK), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Bristol Myers Squibb (BMY) and Tesla (TSLA).

Company Calendar

Last Earnings
7/29/2025
Record date for 9/8 Dividend
8/08/2025
Ex-Dividend for 9/8 Dividend
8/08/2025
Today
8/28/2025
Dividend Payable
9/08/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AZN
CIK
901832
Employees
83,500
Year Founded
1999

Price Target and Rating

High Price Target
$97.00
Low Price Target
$75.00
Potential Upside/Downside
+7.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.66
Trailing P/E Ratio
30.05
Forward P/E Ratio
17.72
P/E Growth
1.47
Net Income
$7.04 billion
Net Margins
14.68%
Pretax Margin
17.74%
Return on Equity
32.84%
Return on Assets
12.87%

Debt

Debt-to-Equity Ratio
0.55
Current Ratio
0.86
Quick Ratio
0.67

Sales & Book Value

Annual Sales
$54.07 billion
Price / Sales
4.58
Cash Flow
$6.28 per share
Price / Cash Flow
12.72
Book Value
$14.45 per share
Price / Book
5.53

Miscellaneous

Outstanding Shares
3,101,360,000
Free Float
N/A
Market Cap
$247.89 billion
Optionable
Optionable
Beta
0.36

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:AZN) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners